MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options
Y Shi, E Taherifard, A Saeed, A Saeed - Current Issues in Molecular …, 2024 - mdpi.com
Hepatocellular carcinoma (HCC) represents a significant burden on global healthcare
systems due to its considerable incidence and mortality rates. Recent trends indicate an …
systems due to its considerable incidence and mortality rates. Recent trends indicate an …
Defining an approach for therapeutic strategies in metabolic dysfunction-associated steatotic liver disease after liver transplantation
Occurrence of metabolic dysfunction associated steatotic liver (MASLD) is common following
liver transplantation (LT). MASLD can be classified as recurrent disease when it occurs in …
liver transplantation (LT). MASLD can be classified as recurrent disease when it occurs in …
[HTML][HTML] Portosystemic shunting prevents hepatocellular carcinoma in non-alcoholic fatty liver disease mouse models
Background and aims Non-alcoholic fatty liver disease (NAFLD) is one of the leading cause
of hepatocellular carcinoma (HCC). This association is supported by the translocation of …
of hepatocellular carcinoma (HCC). This association is supported by the translocation of …
A new prognostic model for accurate assessment of hepatocellular carcinoma risk using RNA editing data and unsupervised machine learning
H Zhu, H Zhang, Y Xiong, H Li - Neurocomputing, 2024 - Elsevier
Abstract A-to-I RNA editing is a long-known driving factor to the progression of
hepatocellular carcinoma (HCC); however, its importance is often neglected in HCC …
hepatocellular carcinoma (HCC); however, its importance is often neglected in HCC …
Early detection of hepatocellular carcinoma: roadmap for improvement
J Melendez-Torres, AG Singal - Expert review of anticancer …, 2022 - Taylor & Francis
Introduction Hepatocellular carcinoma (HCC) has a poor prognosis, related, in part, to
frequent late-stage diagnosis. Improved implementation of effective HCC surveillance is …
frequent late-stage diagnosis. Improved implementation of effective HCC surveillance is …
Efficacy and perioperative safety of different future liver remnant modulation techniques: a systematic review and network meta-analysis
E Bozkurt, JP Sijberden, M Kasai, MA Hilal - HPB, 2024 - Elsevier
Background In daily clinical practice, different future liver remnant (FLR) modulation
techniques are increasingly used to allow a liver resection in patients with insufficient FLR …
techniques are increasingly used to allow a liver resection in patients with insufficient FLR …
[HTML][HTML] Higher risk of tumor recurrence in NASH-related hepatocellular carcinoma following curative resection
SC Chien, YJ Lin, CT Lee, YC Chiu, TC Chou, HC Chiu… - Viruses, 2022 - mdpi.com
Background: The outcomes for patients with NASH-related HCC after curative resection
have not been clarified. This study compared the overall survival (OS), time-to-tumor …
have not been clarified. This study compared the overall survival (OS), time-to-tumor …
[HTML][HTML] Current challenges and future direction in surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease
G Cholankeril, HB El-Serag - Seminars in Liver Disease, 2023 - thieme-connect.com
The burden for hepatocellular carcinoma (HCC) attributed to nonalcoholic fatty liver disease
(NAFLD) continues to grow in parallel with rising global trends in obesity. The risk of HCC is …
(NAFLD) continues to grow in parallel with rising global trends in obesity. The risk of HCC is …
LAYN Serves as a Prognostic Biomarker and Downregulates Tumor-Infiltrating CD8+ T Cell Function in Hepatocellular Carcinoma
S Xiao, L Lu, Z Lin, X Ye, S Su, C Zhang… - Journal of …, 2024 - Taylor & Francis
Background Layilin (LAYN) represents a valuable prognostic biomarker across various
tumor types, while also serving as an innovative indicator of dysfunctional or exhausted …
tumor types, while also serving as an innovative indicator of dysfunctional or exhausted …
[HTML][HTML] Prevalence of metabolic syndrome among patients with hepatocellular carcinoma of different etiologies: a retrospective study
DL Yang, SP Liu, HL Wang, JR Li, JY Su, MJ Li… - Infectious Agents and …, 2024 - Springer
Aims This study compared the prevalences of metabolic syndrome and of cardiac or kidney
comorbidities among patients with hepatocellular carcinoma (HCC) associated with …
comorbidities among patients with hepatocellular carcinoma (HCC) associated with …